Cyramza for EGFR-mutated NSCLC
Compared to placebo, Cyramza appears to give about 7 months of progression-free survival.
Anybody understand why it got such a tepid endorsement from the FDA Advisory committee (6-5 vote) as a 1st-line treatment option?
Compared to placebo, Cyramza appears to give about 7 months of progression-free survival.
Anybody understand why it got such a tepid endorsement from the FDA Advisory committee (6-5 vote) as a 1st-line treatment option?